University College London is to lead a partnership of three institutions on antibody-based drugs for diseases such as cancer, arthritis and multiple sclerosis.
UCL, Imperial College London and The London School of Pharmacy will run the Centre for Innovative Manufacturing in Emergent Macromolecular Therapies with a £4.9 million grant from the Engineering and Physical Sciences Research Council. Another £3.9m will come from 25 industry partners.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.